Ondansetron 2 mg/mL (Ondansetron INJECTION, SOLUTION) 2 mg/mL

Ondansetron 2 mg/mL is a solution injection used to prevent nausea and vomiting. This antiemetic medication is available in single-dose vials for convenient administration.

Strength

2 mg/mL

Pack Size

25 VIAL, SINGLE-DOSE in 1 TRAY (0409-0009-25) / 2 mL in 1 VIAL, SINGLE-DOSE (0409-0009-02)

Manufacturer / TM Owner

Hospira, Inc.

Select Quantity

Pack/s

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

First Name

Last Name

Phone

Delivery Country

Delivery PostCode/Zipcode

Select Your Profile

I have read and agree to the terms & conditions, including the privacy policy, return policy, and usage terms as applicable to this request.

Indications & Clinical Uses

Ondansetron 2 mg/mL is commonly used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, or surgery. It works by blocking serotonin receptors in the brain, which helps to reduce the feeling of nausea. This medication is often administered intravenously or intramuscularly, depending on the patient's needs.

Side Effects

Common effects of Ondansetron 2 mg/mL may include headache, constipation, and dizziness. Some users might also experience fatigue or diarrhea. These effects are generally mild and temporary, but severe or persistent symptoms should be discussed with a healthcare provider.

Precautions & Warnings

Ondansetron 2 mg/mL should be used with caution in patients with a history of heart conditions or electrolyte imbalances. It is important to follow the prescribed dosage and administration instructions carefully. Always inform your healthcare provider about any other medications you are taking to avoid potential interactions.

Avoid Interactions

Ondansetron 2 mg/mL may interact with other medications, including apomorphine, which can cause a dangerous drop in blood pressure. It is also important to be cautious when using Ondansetron with drugs that affect the heart's electrical activity. Always consult a healthcare provider before combining medications.

Frequently Asked Questions

Ondansetron 2 mg/mL is used to prevent nausea and vomiting caused by chemotherapy, radiation therapy, or surgery.

Ondansetron 2 mg/mL can be administered intravenously or intramuscularly, depending on the patient's needs.

Common side effects may include headache, constipation, dizziness, fatigue, and diarrhea.

Ondansetron 2 mg/mL may interact with other medications, so it is important to consult a healthcare provider before combining it with other drugs.

Ondansetron 2 mg/mL should be used with caution in patients with a history of heart conditions or electrolyte imbalances.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated: 29 Jul 2026

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.